Down Syndrome Biomarker Initiative (DSBI)

Launched by MICHAEL RAFII · May 19, 2014

Keywords

ClinConnect Summary

The overall goal of this project is to determine the relationships among the clinical, cognitive, imaging, genetic and biochemical biomarker characteristics of the entire spectrum of Alzheimer's disease (AD), as the pathology evolves from normal aging through very mild symptoms, to mild cognitive impairment (MCI), to dementia in adults with Down syndrome. This is a pilot study modeled after the Alzheimer's Disease Neuroimaging Initiative (ADNI) to inform the neuroscience community of AD in DS, identify diagnostic and prognostic markers, identify outcome measures that can be used in clinical...

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Male and female subjects 30 to 60 years of age inclusive with chromosome karyotype of Down Syndrome due to Trisomy 21.
• • Subjects must have a study partner (parent or other reliable caregiver) who has at least 10 hours of contact and who agrees to accompany the subject to all clinic visits and provide information about the subject's behavior and symptoms.
• • Participant is able to speak/communicate.
• • Subject is willing and has no contraindications to MRI scanning.
• • Participant or parent/legal guardian provides consent.
• • Participant must agree to allow for indefinite storage of his/her data and samples.
• Exclusion Criteria:
• • Patients who are anarthric or mute.
• • Patients who do not meet the criteria for the diagnosis of DS.
• • Patients unwilling or unable to participate in all tests and procedures.
• • Unstable medical or behavioral issues.
• • Unable or unwilling to perform MRI and/or PET imaging.